On Monday, Travere Therapeutics Inc (NASDAQ: TVTX) was 5.78% up from the session before settling in for the closing price of $19.73. A 52-week range for TVTX has been $5.12 – $25.29.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 13.83% over the past five years. When this article was written, the company’s average yearly earnings per share was at 70.49%. With a float of $87.41 million, this company’s outstanding shares have now reached $87.45 million.
Let’s look at the performance matrix of the company that is accounted for 385 employees. In terms of profitability, gross margin is 92.24%, operating margin of -138.0%, and the pretax margin is -137.45%.
Travere Therapeutics Inc (TVTX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Travere Therapeutics Inc stocks. The insider ownership of Travere Therapeutics Inc is 1.50%, while institutional ownership is 109.33%. The most recent insider transaction that took place on Feb 12 ’25, was worth 122,356. In this transaction SENIOR VICE PRESIDENT, R&D of this company sold 5,200 shares at a rate of $23.53, taking the stock ownership to the 98,519 shares. Before that another transaction happened on Feb 12 ’25, when Company’s SVP, GC & CORPORATE SECRETARY sold 8,000 for $23.53, making the entire transaction worth $188,240. This insider now owns 89,482 shares in total.
Travere Therapeutics Inc (TVTX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 70.49% per share during the next fiscal year.
Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators
You can see what Travere Therapeutics Inc (TVTX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.10, a number that is poised to hit -0.55 in the next quarter and is forecasted to reach 0.84 in one year’s time.
Technical Analysis of Travere Therapeutics Inc (TVTX)
Travere Therapeutics Inc (NASDAQ: TVTX) saw its 5-day average volume 1.55 million, a negative change from its year-to-date volume of 1.64 million. As of the previous 9 days, the stock’s Stochastic %D was 75.91%. Additionally, its Average True Range was 1.19.
During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 49.21%, which indicates a significant decrease from 77.02% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.85% in the past 14 days, which was higher than the 54.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.30, while its 200-day Moving Average is $14.89. Nevertheless, the first resistance level for the watch stands at $21.24 in the near term. At $21.62, the stock is likely to face the second major resistance level. The third major resistance level sits at $22.22. If the price goes on to break the first support level at $20.26, it is likely to go to the next support level at $19.66. Assuming the price breaks the second support level, the third support level stands at $19.28.
Travere Therapeutics Inc (NASDAQ: TVTX) Key Stats
There are 88,740K outstanding shares of the company, which has a market capitalization of 1.85 billion. As of now, sales total 233,180 K while income totals -321,550 K. Its latest quarter income was 74,790 K while its last quarter net income were -60,260 K.
